The DEEP Engineering Platform: Redefining Biologics Development
The Directed Evolution Enhancement Platform (DEEP) is revolutionizing the development of protein-based therapeutics. With its proprietary, fully human sequence library, it enables the creation of next-generation biologics across various modalities, including mono and bispecific molecules, as well as antibody-drug conjugates (ADCs). These advanced therapies can bind to their targets up to 10,000 times more effectively, delivering unmatched potency. Designed for superior biological properties and easier manufacturing, DEEP overcomes the toughest challenges in drug development, accelerating the path to groundbreaking treatments.
AI-Powered Speed: From Months to Weeks
With cutting-edge AI integration, DEEP is transforming the speed of drug discovery. By seamlessly combining AI predictions with lab automation, the platform reduces discovery timelines from six months to as little as eight weeks or even faster. Leveraging a vast, pre-validated proprietary protein database, DEEP eliminates the need for costly and time-consuming de novo sequencing. This approach accelerates breakthroughs, lowers costs, and delivers life-saving treatments to patients sooner.
Breaking Boundaries with Hard-to-Express Proteins
DEEP is the first platform to unlock the expression of challenging proteins like GPCRs using a game-changing liposome-based system. These complex proteins regulate multiple signaling pathways, making them key targets for highly specific therapies. With DEEP, we can develop drugs that precisely target the desired pathways while avoiding unwanted effects on others. A prime study case is our breakthrough with C5aR, our team engineered a bias clone that selectively inhibits G protein-mediated recruitment of cAMP without affecting β-Arrestin. This innovation paves the way for safer, more accurate treatments that deliver targeted results.